BTIG Rates ICU Medical (ICUI) buy, $170 Price Target
BTIG reaffirms its buy stance on ICUI, setting a $170 price target, a 19.55% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
BTIG rated ICU Medical, Inc. ($ICUI) "buy" with a $170 price target on June 15, 2026.
Since the rating, $ICUI is down 5.3% after 1 week, up 9.9% after 1 month and up 13.4% to date (from the $143.72 close on Jun 15, 2026).
ICUI
ICU Medical, Inc.
Key Points
- On June 15, 2026, BTIG reiterated its buy rating for ICUI, setting a price target of $170.
- BTIG's $170 price target implies 19.55% upside from ICU Medical, Inc.'s ($ICUI) current $142.20 share price.
- ICUI shares traded at $142.2, with significant insider and institutional investor activity noted.
- Insider sales and various institutional changes highlight the dynamic interest in ICUI's stock.
Get $ICUI trade alerts by text
We text you when insiders, Congress or big funds trade $ICUI. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated ICU Medical, Inc. alert may contain errors. Disclosures
BTIG reaffirmed its positive outlook on ICUI by reiterating a buy rating and setting a price target of $170 on June 15, 2026. This comes as ICUI's shares were trading at $142.2, reflecting the firm's confidence in the company's potential upside.
Other Institutional Activity in ICUI
BlackRock, Inc. increased its holdings in ICUI by 20,167 shares, bringing its total to about 3,608,322 shares valued at approximately $466.0 million. Janus Henderson Group PLC also boosted its position by 99,256 shares, now holding 2,676,012 shares worth about $345.6 million. On the other hand, Fuller & Thaler Asset Management, Inc. reduced its stake by 45,260 shares, leaving it with 1,220,539 shares valued at around $157.6 million. Dimensional Fund Advisors LP saw a notable increase, adding 63,026 shares to hold a total of 983,802 shares valued at $127.1 million.
ICU Medical, Inc. Stock Down 6.8%
Shares of ICUI traded near $142.2 recently. While specific financial ratios and metrics aren't available, the stock's current price suggests active trading interest. Investors should note the dynamic changes in institutional holdings as a potential indicator of market sentiment.
$ICUI price target
ICU Medical, Inc. daily closes and this analyst's $170 target. Not advice.
Insider Buying and Selling at ICU Medical, Inc.
Recent insider transactions at ICUI included President Daniel Woolson selling 2,123 shares at an average price of $132.21 on May 22, 2026. Virginia Ruth Sanzone, Vice President and General Counsel, sold 2,447 shares at $124.08 on May 14, 2026. Additionally, on May 13, 2026, David Greenberg, David Hoffmeister, and Elisha Finney each bought 1,254, 1,254, and 1,475 shares respectively, although these purchases were recorded at a price of $0, indicating possible stock grants or options.
Analysts Set New Price Targets
On June 15, 2026, BTIG initiated a buy rating on ICUI with a $170 price target. Earlier, on May 27, 2026, Needham upgraded ICUI to a buy with a $165 target. Keybanc and Piper Sandler have consistently maintained buy ratings, with targets ranging from $163 to $180 over recent months. The consensus among analysts remains positive, with a strong buy recommendation and an average target price reflecting optimism in ICUI's future prospects.
Bottom Line
BTIG's reiterated buy rating and $170 price target underscore continued confidence in ICUI's growth potential. The stock's recent trading activity, coupled with insider transactions and shifts in institutional holdings, highlights the ongoing interest and potential volatility in ICUI's market performance. As always, 13F filings and analyst ratings offer valuable insights but are backward-looking and should be considered as part of a broader research strategy.
Related Filing Alerts
Source: BTIG's rating change on $ICUI (Jun 15, 2026). Written by software, not financial advice. How we make alerts